BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of March 23, 2026, BMY stock price declined to $57.00 with 8,763,821 million shares trading.

BMY has a beta of 0.52, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.09 to the broad based SPY ETF.

BMY has a market cap of $115.98 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $13 billion in Revenue and $1.26 earnings per share. This beat revenue expectation by $236 million and exceeded earnings estimates by $.07.

In the last 3 years, BMY traded as high as $71.07 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): SCHD, VTI, VOO, IVV, SPY.

BMY has underperformed the market in the last year with a price return of -1.5% while the SPY ETF gained +17.9%. However, in the short term, BMY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.3% vs -3.4% return in SPY. But in the last 2 weeks, BMY shares have been beat by the market, returning -5.5% compared to an SPY return of -2.3%.

BMY support price is $56.71 and resistance is $58.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.